Actively Recruiting
Phase 3 Trial Comparing Metastasis-Directed Therapy Versus Standard Care for Men with Oligoprogressive Castration-Refractory Prostate Cancer
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-09-05
246
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the impact of progression-directed therapy in patients with castration-refractory prostate cancer who have up to 5 progressing lesions. This phase 3, randomized, open-label trial aims to compare overall survival in patients with oligoprogressive metastatic castration-resistant prostate cancer mCRPC. Patients are grouped based on number and location of metastases and systemic therapy type before randomization, which follows approval by a multidisciplinary tumor board. Participants are randomly assigned to one of two groups. One group receives standard care, which may include surveillance with ongoing systemic treatment or starting new systemic treatments such as abiraterone acetate, enzalutamide, apalutamide, chemotherapy, or radionuclide therapy. The other group receives progression-directed therapy either metastasectomy or stereotactic body radiation therapy while continuing their current systemic treatment, except for those currently on docetaxel. If new lesions appear after progression-directed therapy, repeated therapy is required. During the study, participants will have regular assessments including imaging every 6 months or as needed, and quality of life questionnaires at baseline and several follow-up points up to 24 months. Researchers will monitor overall survival up to 5 years, cancer-specific survival, radiographic progression-free survival, and treatment-related toxicity. This comprehensive monitoring will help determine the effects of progression-directed therapy in this patient population.
CONDITIONS
Brief Title
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Research Team
K
Kato Rans, MD
G
Gert De Meerleer, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here